- In April 2024, Zoetis Inc., a global leader in animal health, announced the expansion of its manufacturing capabilities in Ireland to meet growing demand for veterinary antibiotics and biologics. This strategic investment aims to support the increasing need for disease prevention and treatment in both companion and livestock animals across global markets. The facility will focus on producing high-quality antibiotic injectables and oral formulations, reinforcing Zoetis' commitment to sustainable animal healthcare and global supply chain resilience
- In March 2024, Elanco Animal Health Incorporated introduced Kavaxen, a next-generation antibiotic developed for respiratory infections in cattle. The product utilizes a novel formulation to enhance efficacy and reduce withdrawal times, supporting responsible antibiotic use in food-producing animals. This launch demonstrates Elanco’s innovation-driven approach and alignment with global efforts to combat antimicrobial resistance while maintaining livestock productivity
- In February 2024, Boehringer Ingelheim announced a research collaboration with academic institutions in the EU to develop antibiotic stewardship programs tailored for veterinary applications. The initiative focuses on promoting precision antibiotic usage through diagnostics and real-time data analytics in livestock farming. This development reflects a growing industry trend towards stewardship and sustainability in antibiotic administration
- In January 2024, Virbac launched a comprehensive antibiotic portfolio in Southeast Asia, addressing the rising demand for accessible veterinary treatments in emerging markets. The company’s strategy includes the introduction of targeted solutions for common bacterial infections in poultry, swine, and aquaculture, strengthening its position in rapidly growing animal health markets and improving access to essential medicines
- In December 2023, Ceva Santé Animale announced the completion of its acquisition of a veterinary antibiotic production facility in Latin America. This acquisition is aimed at expanding the company’s footprint in the region and increasing the availability of injectable and oral antibiotics for livestock. The move aligns with Ceva’s strategy to reinforce its supply chain, meet regional demand, and promote responsible antibiotic practices across Latin America
